Literature DB >> 20718817

Molecular therapy drives patient-centric health care paradigms.

Scott A Waldman1, Andre Terzic.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20718817      PMCID： PMC2946388          DOI： 10.1111/j.1752-8062.2010.00203.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  25 in total

Review 1.  Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?

Authors:  A E Shields; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

2.  Pharmacogenetics: from bench to byte.

Authors:  J J Swen; I Wilting; A L de Goede; L Grandia; H Mulder; D J Touw; A de Boer; J M H Conemans; T C G Egberts; O H Klungel; R Koopmans; J van der Weide; B Wilffert; H-J Guchelaar; V H M Deneer
Journal:  Clin Pharmacol Ther       Date:  2008-02-06       Impact factor: 6.875

3.  Clinical pharmacology in the molecular era.

Authors:  C T Dollery
Journal:  Clin Pharmacol Ther       Date:  2008-02       Impact factor: 6.875

4.  The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.

Authors:  J A Sollano; J M Kirsch; M V Bala; M G Chambers; L H Harpole
Journal:  Clin Pharmacol Ther       Date:  2008-06-11       Impact factor: 6.875

Review 5.  Lazarus's gate: challenges and potential of epigenetic reprogramming of somatic cells.

Authors:  J T Henderson
Journal:  Clin Pharmacol Ther       Date:  2008-03-26       Impact factor: 6.875

Review 6.  Development of translational pharmacokinetic-pharmacodynamic models.

Authors:  D E Mager; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  2008-03-26       Impact factor: 6.875

7.  Therapeutic targeting: a crucible for individualized medicine.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2008-05       Impact factor: 6.875

8.  Economic evaluation of pharmacogenetic tests.

Authors:  A C Wu; A L Fuhlbrigge
Journal:  Clin Pharmacol Ther       Date:  2008-06-25       Impact factor: 6.875

9.  The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.

Authors:  K Romero; M de Mars; D Frank; M Anthony; J Neville; L Kirby; K Smith; R L Woosley
Journal:  Clin Pharmacol Ther       Date:  2009-10       Impact factor: 6.875

10.  Vaccine development in the twenty-first century: changing paradigms for elusive viruses.

Authors:  B S Graham; J E Ledgerwood; G J Nabel
Journal:  Clin Pharmacol Ther       Date:  2009-09       Impact factor: 6.875
View more
  8 in total

Review 1.  Widening the path to personalized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

2.  Clinical and translational science: from bench-bedside to global village.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

3.  Chronic diseases: the emerging pandemic.

Authors:  Andre Terzic; Scott Waldman
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

4.  Clinical translational science 2020: disruptive innovation redefines the discovery-application enterprise.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

5.  Bionic technologies transforming the science of healthcare delivery.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2011-04       Impact factor: 4.689

6.  Regenerative medicine: on the vanguard of health care.

Authors:  Andre Terzic; Clifford D Folmes; Almudena Martinez-Fernandez; Atta Behfar
Journal:  Mayo Clin Proc       Date:  2011-07       Impact factor: 7.616

7.  The value proposition of molecular medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2012-02-23       Impact factor: 4.689

8.  Clinical pharmacology at the core of translational science.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Expert Rev Clin Pharmacol       Date:  2011-05       Impact factor: 5.045
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.